The classical stament holds so good here, that there's no use beating the line after the snake has passed , the act in which Pfizer is involved in , trying to counterbid Daichi offer made to Ranbaxy. Sources at Ranbaxy have confirmed that there is no going back on the deal and the deal with Daichi is final and agreed upon.
It is true that the company (Pfizer ) and many other competitors were caught sleeping and taken by surprise when the news of takeover was announced.
Daichi wants to increase its shareholding in the company to 51% for which it wants to make an open offer to the market.
whereas Pfizer, the world's largest drug maker, may bid for the about 65 percent of Ranbaxy held by institutions and public shareholders.
well the scene is set for a battle royale for the India's no 1 generic drug maker company.
No comments:
Post a Comment